Inhaled budesonide for early treatment of COVID-19 – authors' reply

Authors/Creators

Sanjay Ramakrishnan, Edith Cowan UniversityFollow
Mona Bafadhel

Abstract

We share the enthusiasm of Rafael San-Juan and colleagues, Markus Zeitlinger and Marco Idzko, and Jae Chol Choi and Won-Young Kim in the search for an effective treatment in early COVID-19, and in the findings of the STOIC study.

Document Type

Letter to the Editor

Date of Publication

2021

Volume

9

Issue

7

PubMed ID

33991509

School

School of Medical and Health Sciences

Copyright

free_to_read

Publisher

Elsevier

Comments

Ramakrishnan, S., & Bafadhel, M. (2021). Inhaled budesonide for early treatment of COVID-19–authors' reply. The Lancet Respiratory Medicine, 9(7), e61. https://doi.org/10.1016/S2213-2600(21)00212-5

Recommended Citation

Ramakrishnan, S., & Bafadhel, M. (2021). Inhaled budesonide for early treatment of COVID-19 – authors' reply. DOI: https://doi.org/10.1016/S2213-2600(21)00212-5